Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMT-100948
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BMT-100948 is a metabolite of **BMS-986115**, an orally active small molecule gamma-secretase inhibitor (GSI) developed by **Bristol Myers Squibb**. BMS-986115 was designed to selectively inhibit Notch signaling, a pathway that plays a critical role in the maintenance of cancer stem cells and the promotion of tumor angiogenesis. BMT-100948 was characterized during Phase I clinical trials in patients with advanced solid tumors to evaluate the steady-state pharmacokinetics and metabolic profile of the parent compound. The development of these inhibitors represents a strategy to target Notch-mediated oncogenic signaling in various malignancies.
02
Targets
GSEC (Gamma-Secretase Complex)
Beyond the preview
Go deeper on BMT-100948.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMT-100948.